Images List Premium Download Classic

Dysfunction

Dysfunction-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Amorphous hyaluronic acid-magnesium/calcium polyphosphate microparticles for cartilage regeneration and repair
Nanotecmarin Gmbh
January 18, 2018 - N°20180015205

This invention concerns a biomimetic material based on energy-rich amorphous magnesium polyphosphate (mg-polyp) microparticles that enhance cartilage synthesis and regeneration. One preferred formulation of the inventive material is a hyaluronic acid-mg/ca-polyp paste that can be produced from a water-soluble salt of polyp and water-soluble hyaluronic acid in the presence of water-insoluble/nearly insoluble calcium carbonate. Surprisingly, the inventor found ...
Ghrelin analogues
Zealand Pharma A/s
January 11, 2018 - N°20180009849

The present invention relates, inter alia, to ghrelin analogues and their medical use, for example in the treatment of cachexia, chronic obstructive pulmonary disease, gastrointestinal disorders (e. G., gastroparesis and/or inflammatory disorders such as colitis, gut barrier dysfunction, and ischemia reperfusion injury), loss of body weight, and decreased appetite.
Inhibitors of trka kinase
Gvk Biosciences Private Limited
January 11, 2018 - N°20180009781

The present invention is directed to the compounds of formula i which are inhibitors of tropomyosin-related kinase a (trka): formula (i) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, ra, rb, rc, rd, r1, r2, l and het-ar are as defined herein. These compounds can be used for the preventive and/or therapeutic ...
Dysfunction Patent Pack
Download 289+ patent application PDFs
Dysfunction Patent Applications
Download 289+ Dysfunction-related PDFs
For professional research & prior art discovery
inventor
  • 289+ full patent PDF documents of Dysfunction-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Positive allosteric modulators of the muscarinic acetylcholine receptor m4
Vanderbilt University
December 28, 2017 - N°20170369505

Disclosed herein are tricyclic compounds, including pyrimido[4′,5′:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2′,3′:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3′,2′:4,5]furo[3, 2-d]pyrimidin-4-amine, and pyrimido[4′,5′:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4). Also ...
Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
Deuterx, Llc
December 28, 2017 - N°20170369420

The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched bupropion. A preferred aspect of the invention provides methods of treating obesity and sexual dysfunction using enantiopure deuterium-enriched bupropion.
Polymeric nanoparticle
December 28, 2017 - N°20170368181

In a third aspect, the invention provides a polymeric nanoparticle according to the first aspect of the present invention, or a polymeric nanoparticle prepared according to the second aspect of the present invention; for use in the treatment of an inflammatory and/or arthritic disorder caused by or associated with dysfunctional nuclear receptor signalling.
Dysfunction Patent Pack
Download 289+ patent application PDFs
Dysfunction Patent Applications
Download 289+ Dysfunction-related PDFs
For professional research & prior art discovery
inventor
  • 289+ full patent PDF documents of Dysfunction-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel condom comprising cannabis derived compositions for enhancement of sexual pleasure and decrease of erectile ...
One World Cannabis Ltd
December 28, 2017 - N°20170367875

The present invention provides a biocompatible polymer or biocompatible material or composition for forming at least part of the structure of a condom useful for preventing sti's. The biocompatible polymer incorporates cannabis or cannabis derived compositions. The present invention also provides a biocompatible additive for condoms incorporating cannabis or cannabis derived compositions in a carrier or excipient. In addition, the ...
Optical network unit reset message
Futurewei Technologies, Inc.
December 21, 2017 - N°20170366254

A low-level reset message having a reset level provides a mechanism for an optical line terminal (olt) to remotely reset a dysfunctional optical network unit (onu). The reset message includes a reset level field which allows the olt to instruct the onu to perform a reset of some or all of its hardware and software components.
Optical network unit reset message
Futurewei Technologies, Inc.
December 21, 2017 - N°20170366253

A low-level reset message having a reset level provides a mechanism for an optical line terminal (olt) to remotely reset a dysfunctional optical network unit (onu). The reset message includes a reset level field which allows the olt to instruct the onu to perform a reset of some or all of its hardware and software components.
Apparatus for the treatment of female sexual dysfunction
December 21, 2017 - N°20170361109

There is disclosed an apparatus for treating a sexual dysfunctional female patient, comprising an implanted stimulation device adapted to stimulate at least a part of the vagina of the patient by movement of said stimulation device and contact between said stimulation device and the sexually responsive tissue or the wall of the vagina. A system and an operation method for ...
Extracellular vesicles with enhanced potency
United Therapeutics Corporation
December 21, 2017 - N°20170360840

Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction.
Materials and methods for treating endothelial dysfunction and methods for monitoring efficacy of therapy in ...
University Of Miami
December 21, 2017 - N°20170360837

The present disclosure is directed to materials and methods for treating endothelial dysfunction in a subject in need thereof. Methods of determining efficacy of treatment are also provided.
Compositions and methods for treating intestinal hyperpermeability
December 21, 2017 - N°20170360736

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic ...
Dysfunction Patent Pack
Download 289+ patent application PDFs
Dysfunction Patent Applications
Download 289+ Dysfunction-related PDFs
For professional research & prior art discovery
inventor
  • 289+ full patent PDF documents of Dysfunction-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease ...
FundaciÓn Para La InvestigaciÓn MÈdica Aplicada
December 14, 2017 - N°20170356060

The invention relates to a nucleic acid construct carrying atp7b protein, an expression vector and a viral particle comprising the nucleic acid construct, and their use for treatment of wilson's disease and other conditions caused by a deficiency or dysfunction of atp7b protein. An aav vector devised according to the invention significantly reduced urine cu excretion, and liver ...
Novel oxazole compounds as beta catenin modulators and uses thereof
December 14, 2017 - N°20170355686

Are provided as inhibitors of the wnt pathway that specifically target the activity of the stabilized pool of β-cat. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cancer, and other conditions related to wnt ...
Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
December 14, 2017 - N°20170354640

The disclosure provides thiol-containing alkyl fatty acid and vitamin d compound formulations for intravenous, parenteral or oral administration. The compositions of the present technology have optimal controlled bioavailability and are useful for treating metabolic dysfunctions such as pre-diabetes, metabolic syndrome and diabetes. Also provided are methods of treatment comprising the daily administration of the disclosed thiolcontaining alkyl fatty acid formulations ...
Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
December 07, 2017 - N°20170349597

The compound of chemical formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mglur5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mglur5.
Compositions and methods for treating neurodegenerative disease
Cognition Therapeutics, Inc.
December 07, 2017 - N°20170349554

This invention relates to the use sigma-2 receptor antagonists, and of pharmaceutical compositions comprising such compounds, in methods for inhibiting abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with abeta pathology and more broadly treating with such compounds and compositions neurodegenerative diseases and disorders associated ...
Transcutaneous stimulation method and system
Murdoch Childrens Research Institute
December 07, 2017 - N°20170348526

A method of treating a waste evacuation dysfunction comprising administering transcutaneous electrical stimulation (tes) to at least one lower pelvic and/or sacral region for a specific treatment regimen. Also disclosed is a system for configuring a stimulation device to deliver transcutaneous electrical stimulation (tes) the system comprising: a computing device storing or having access to a plurality of tes ...
Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease
FundaciÓn Para La InvestigaciÓn MÈdica Aplicada
December 07, 2017 - N°20170348435

The invention relates to nucleic acid constructs and gene therapy vectors that comprise an atp7b variant for use in the treatment of conditions associated with a deficiency or dysfunction of copper-transporting atpase 2, and particularly of wilson's disease. An aav vector devised according to the invention significantly reduced urine cu excretion, and liver cu content in wilson's disease mice treated ...
Transgenic rpe cells overexpressing otx2 for the treatment of retinal degeneration
Inserm (institut National De La Sante Et De La Recherche Medicale)
December 07, 2017 - N°20170348434

The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.
Loading